Biocius and BlueSky to Develop Sirtuin Enzymes Validated Using Label-Free Assays
June 18, 2010
Biocius and BlueSky to Develop Sirtuin Enzymes Validated Using Label-Free Assays
The collaboration, which builds on an existing partnership between the two companies, has the potential to improve the drug discovery efficiency of SIRT epigenetic modulating enzymes, which have been implicated in processes such as insulin signaling, apoptosis, and cancer.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- SuppreMol to Use Protagen Biomarker Panel
August 2, 2011 / GenomeWeb Daily News - People In The News
July 1, 2011 / GenomeWeb Daily News - Affymetrix's Shares Jump 30 Percent in June to Lead GWDN Index
July 1, 2011 / GenomeWeb Daily News - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - Adarza Aims to Launch Biomarker Detection Platform Next Year; Adds Former Roche CEO to Board
June 3, 2011 / ProteoMonitor